Pneumonia in the elderly

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 3, 2009, Pages 223-229

  Cabre, Mateo ^a  

^a HOSPITAL DE MATARÓ   (Spain)

Author keywords

Aged over 80; Aspiration pneumonia; Community acquired pneumonia; Elderly; Prevention

Indexed keywords

AMANTADINE; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CABERGOLINE; CAPSAICIN; CD14 ANTIGEN; CEFTRIAXONE; CILOSTAZOL; CLARITHROMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; INFLUENZA VACCINE; LEVOFLOXACIN; MACROLIDE; MANNOSE BINDING LECTIN; MOXIFLOXACIN; PNEUMOCOCCUS VACCINE; PROCALCITONIN; PROTON PUMP INHIBITOR; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; ANTIVIRUS AGENT;

AGED; ANTIBIOTIC THERAPY; ASPIRATION PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; COST OF ILLNESS; DIABETES MELLITUS; DYSPHAGIA; ESCHERICHIA COLI; HOSPITAL READMISSION; HUMAN; INCIDENCE; LEGIONELLA PNEUMOPHILA; MORTALITY; MOUTH HYGIENE; MYCOPLASMA PNEUMONIAE; PROGNOSIS; REVIEW; RISK FACTOR; SMOKING; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; VACCINATION; VERY ELDERLY; AGE; BACTERIAL PNEUMONIA; PATHOGENICITY;

AGE FACTORS; ANTIVIRAL AGENTS; HUMANS; PNEUMONIA, ASPIRATION; PNEUMONIA, BACTERIAL; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 67649216901     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328326f571     Document Type: Review

References (90)

1. Lee CC, Chen SY, Chang IJ, et al. Comparison of clinical manifestations and outcome of community-acquired bloodstream infections among the oldest old, elderly, and adult patients. Medicine (Baltimore) 2007; 86:138-144.
2. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in Eastern Europe. Am J Epidemiol 1993; 137:977-988.
3. Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002; 165:766-772.
4. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of communityacquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39:1642-1650.
5. Ochoa-Gondar O, Vila-Córcoles A, de Diego C, et al., EVAN-65 Study Group. The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study. BMC Public Health 2008; 8:222.
6. Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis 2008; 14:727-733.
7. Kollef MH, Morrow LE, Baughman RP, et al. Healthcare-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes: proceedings of the HCAP Summit. Clin Infect Dis 2008; 46 (S4):S296-S334.
8. Charles PG, Whitby M, Fuller AJ, et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis 2008; 46:1513-1521.
9. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community acquired pneumonia: prevalence, pathogens and presentation. Chest 2008; 134:1141-1148.
10. Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; 63:42-48.
11. D́az A, Barria P, Niederman M, et al. Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest 2007; 131:779-787.
12. Camps Serra M, Cervera C, Pumarola T, et al. Virological diagnosis in community-acquired pneumonia in immunocompromised patients. Eur Respir J 2008; 31:618-624.
13. Weatherall C, Paoloni R, Gottlieb T. Point-of-care urinary pneumococcal antigen test in the emergency department for community acquired pneumonia. Emerg Med J 2008; 25:144-148.
14. den Boer JW, Yzerman EP, Schellekens J, et al. A large outbreak of Legionnaires' disease at a flower show, the Netherlands, 1999. Emerg Infect Dis 2002; 8:37-43.
15. Sopena N, Pedro-Botet L, Mateu L, et al. Community-acquired legionella pneumonia in elderly patients: characteristics and outcome. J Am Geriatr Soc 2007; 55:114-119.
16. Sopena N, Force L, Pedro-Botet ML, et al. Sporadic and epidemic community legionellosis: two faces of the same illness. Eur Respir J 2007; 29:138-142.
17. Ruiz LA, Zalacain R, Gómez A, et al. Escherichia coli: an unknown and infrequent cause of community acquired pneumonia. Scand J Infect Dis 2008; 40:424-427.
18. Almirall J, Bolíbar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 2008; 31:1274-1284.
19. Skull SA, Andrews RM, Byrnes GB, et al. Hospitalized community-acquired pneumonia in the elderly: an Australian case-cohort study. Epidemiol Infect 2008; 18:1-9.
20. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med 2008 [Epub ahead of print].
21. Kornum JB, Thomsen RW, Riis A, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 2008; 31:1541-1545.
22. Knol W, van Marum RJ, Jansen PA, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008; 56:661-666.
23. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149:391-398.
24. Kikuchi R, Watabe N, Konno T, et al. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994; 150:251-253.
25. Fernandez-SabéN, Carratalà J, Rosón B, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore) 2003; 82:159-169.
26. Quagliarello V, Ginter S, Han L, et al. Modifiable risk factors for nursing homeacquired pneumonia. Clin Infect Dis 2005; 40:1-6.
27. Teramoto S, Fukuchi Y, Sasaki H, et al. High incidence of aspiration pneumonia in community and hospital-acquired pneumonia in hospitalized patients: a multicenter, prospective study in Japan. J Am Geriatr Soc 2008; 56:577-579.
28. Almirall J, CabréM, ClavéP. Aspiration pneumonia. Med Clin (Barc) 2007; 129:424-432.
29. Marik PE, Kaplan D. Aspiration pneumonia and dysphagia in the elderly. Chest 2003; 124:328-336.
30. Garcia-Vidal C, Fernández-SabéN, Carratalà J, et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J 2008; 32:733-739.
31. Chalmers JD, Singanayagam A, Hill AT. Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia. Thorax 2008; 63:698-702.
32. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47:375-384.
33. Zilberberg MD, Exuzides A, Spalding J, et al. Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study. BMC Pulmon Med 2008; 8:16.
34. Nair V, Niederman MS, Masani N, Fishbane S. Hyponatremia in communityacquired pneumonia. Am J Nephrol 2007; 27:184-190.
35. Torres OH, Muñoz J, Ruiz D, et al. Outcome predictors of pneumonia in elderly patients: importance of functional assessment. J Am Geriatr Soc 2004; 52:1603-1609.
36. Mody L, Sun R, Bradley SF. Assessment of pneumonia in older adults: effect of functional status. J Am Geriatr Soc 2006; 54:1062-1067.
37. CabréM, Serra-Prat M, Force L, et al. Functional status as a risk factor for mortality in very elderly patients with pneumonia. Med Clin (Barc) 2008; 131:167-170.
38. Kothe H, Bauer T, Marre R, et al., Competence Network for Community- Acquired Pneumonia study group. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008; 32:139-146.
39. Zalacain R, Torres A, Celis R, et al. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur Respir J 2003; 21:294-302.
40. CabréM, Serra-Prat M, Bolíbar I, et al. Prognostic factors of community acquired pneumonia in very old patients. Med Clin (Barc) 2006; 127:201-205.
41. Mehr DR, Binder EF, Kruse RL, et al. Predicting mortality in nursing home residents with lower respiratory tract infection: The Missouri LRI Study. JAMA 2001; 286:2427-2436.
42. Marrie TJ, Wu L. Factors influencing in-hospital mortality in communityacquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 2005; 127:1260-1270.
43. Menendez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008; 63:447-452.
44. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121:219-225.
45. Krüger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31:349-355.
46. Porcel JM, Galindo C, Esquerda A, et al. Pleural fluid interleukin-8 and C-reactive protein for discriminating complicated nonpurulent from uncomplicated parapneumonic effusions. Respirology 2008; 13:58-62.
47. Garcia-Laorden MI, Sole-Violan J, Rodriguez de Castro F, et al. Mannosebinding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. J Allergy Clin Immunol 2008; 122:368-374.
48. Yende S, D'Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177:1242-1247.
49. Schuetz P, Stolz D, Mueller B, et al. Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. BMC Infect Dis 2008; 8:22.
50. van de Garde EM, Endeman H, Deneer VH, et al. Angiotensin-converting enzyme (ACE) I/D corrected serum ACE activity and severity assessment of community-acquired pneumonia. Clin Chem Lab Med 2007; 45:1326-1331.
51. Christ-Crain M, Stolz D, Jutla S, et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 176:913-920.
52. Aalto H, Takala A, Kautiainen H, et al. CD14 and soluble CD14 in predicting mortality of patients with severe community acquired infection. Scand J Infect Dis 2007; 39:596-603.
53. Tejera A, Santolaria F, Diez ML, et al. Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine 2007; 38:117-123.
54. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008; 121:1002-1007.
55. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin- converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008; 31:611-617.
56. Krüger S, Papassotiriou J, Marre R, et al. Pro-atrial natriuretic peptide and provasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med 2007; 33:2069-2078.
57. MasiáM, Papassotiriou J, Morgenthaler NG, et al. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem 2007; 53:2193-2201.
58. Prat C, Lacoma A, Dominguez J, et al. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. J Infect 2007; 55:400-407.
59. Cabre M, Bolivar I, Pera G, et al. Factors influencing length of hospital stay in community-acquired pneumonia: a study in 27 community hospitals. Epidemiol Infect 2004; 132:821-829.
60. Garau J, Baquero F, Pérez-Trallero E, et al. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect 2008; 14:322-329.
61. Capelastegui A, España PP, Quintana JM, et al. Declining length of hospital stay for pneumonia and postdischarge outcomes. Am J Med 2008; 121:845-852.
62. El Solh A, Pineda L, Bouquin P, Mankowski C. Determinants of short and long term functional recovery after hospitalization for community-acquired pneumonia in the elderly: role of inflammatory markers. BMC Geriatr 2006; 9:12.
63. Reyes S, Martinez R, Vallés JM, et al. Determinants of hospital costs in community-acquired pneumonia. Eur Respir J 2008; 31:1061-1067.
64. Asche C, McAdam-Marx C, Seal B, et al. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother 2008; 61:1162-1168.
65. Torres A, Garau J, Arvis P, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study - a randomized clinical trial. Clin Infect Dis 2008; 46:1499-1509.
66. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a metaanalysis. Drugs 2008; 68:1841-1854.
67. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174:84-93.
68. Tamm M, Todisco T, Feldman C, et al. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study. Clin Microbiol Infect 2007; 13:162-171.
69. Shorr AF, Khashab MM, Xiang JX, et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med 2006; 100:2129-2136.
70. Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008; 168:351-356.
71. Salluh JI, Póvoa P, Soares M, et al. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care 2008; 12:R76.
72. Garcia-Vidal C, Calbo E, Pascual V, et al. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007; 30:951-956.
73. Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007; 185:249-255.
74. Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 2008; 62:661-668.
75. Gorman SK, Slavik RS, Marin J. Corticosteroid treatment of severe community-acquired pneumonia. Ann Pharmacother 2007; 41:1233-1237.
76. Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008; 47:182-187.
77. Jasti H, Mortensen EM, Obrosky DS, et al. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 2008; 46:550-556.
78. Capelastegui A, España PP, Bilbao A, et al. Pneumonia: criteria for patient instability on hospital discharge. Chest 2008; 134:595-600.
79. Yende S, Angus DC, Ali IS, et al. Influence of comorbid conditions on longterm mortality after pneumonia in older people. J Am Geriatr Soc 2007; 55:518-525.
80. El Solh AA, Saliba R. Pharmacologic prevention of aspiration pneumonia: a systematic review. Am J Geriatr Pharmacother 2007; 5:352-362.
81. Robbins J, Gensler G, Hind J, et al. Comparison of 2 interventions for liquid aspiration on pneumonia incidence: a randomized trial. Ann Intern Med 2008; 148:509-518.
82. Sjögren P, Nilsson E, Forsell M, et al. A systematic review of the preventive effect of oral hygiene on pneumonia and respiratory tract infection in elderly people in hospitals and nursing homes: effect estimates and methodological quality of randomized controlled trials. J Am Geriatr Soc 2008; 56:2124-2130.
83. Ishikawa A, Yoneyama T, Hirota K, et al. Professional oral healthcare reduces the number of oropharyngeal bacteria. J Dent Res 2008; 87: 594-598.
84. Logemann JA, Gensler G, Robbins J, et al. A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson's disease. J Speech Lang Hear Res 2008; 51:173-183.
85. Iwasaki K, Kato S, Monma Y, et al. A pilot study of banxia houpu tang, a traditional Chinese medicine, for reducing pneumonia risk in older adults with dementia. J Am Geriatr Soc 2007; 55:2035-2040.
86. Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007; 167:1938-1943.
87. Ochoa-Gondar O, Vila-Corcoles A, Ansa X, et al. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. Vaccine 2008; 26:1955-1962.
88. Hak E, Sanders EA, Verheij TJ, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378-383.
89. Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in patients with pneumonia outside 'flu' season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med 2008; 178:527-533.
90. Jackson ML, Nelson JC, Weiss NS, et al. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population- based, nested case-control study. Lancet 2008; 372:398-405.